Back to top

Merrimack Pharmaceuticals, Inc. (MACK) Appears Robust as Stock Shoots up 59.2%
May 02, 2014

Read MoreHide Full Article

Merrimack Pharmaceuticals, Inc. (MACK - Free Report) was a big mover last session, as the company saw its shares surge a whopping 59.2% on the day. This tremendous rally can be attributable to solid volume too with far more shares changing hands than in a normal session. This broke the recent trend of the company, as the stock is now trading above the volatile price range of $4.39 to $5.35 in the past one-month time frame.

In the last 30 days, this company did not witness any estimate revisions while its Zacks Consensus Estimate, which is pegged at a loss, narrowed over the same period, suggesting that more solid trading could be ahead for Merrimack Pharmaceuticals. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.

Merrimack Pharmaceuticals currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Other better-ranked players in the healthcare industry include Enanta Pharmaceuticals, Inc. (ENTA - Free Report) , Gilead Sciences Inc. (GILD - Free Report) and TrovaGene, Inc. all carrying a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Merrimack Pharmaceuticals, Inc. (MACK) - free report >>

Enanta Pharmaceuticals, Inc. (ENTA) - free report >>

Gilead Sciences, Inc. (GILD) - free report >>

More from Zacks Tale of the Tape

You May Like